Advertisement

Molecular and Cellular Biochemistry

, Volume 461, Issue 1–2, pp 65–72 | Cite as

Azoramide improves mitochondrial dysfunction in palmitate-induced insulin resistant H9c2 cells

  • Esma Nur Okatan
  • Yusuf Olgar
  • Erkan Tuncay
  • Belma TuranEmail author
Article

Abstract

Azoramide is identified as a new compound with the dual properties for the improvement of ER-folding capacity in various cells as well as for the treatment of T2DM. Although the effect of azoramide in glucose-homeostasis in mammalians is not known very well, a limited number of experimental studies showed that it could improve the insulin sensitivity in genetically obese mice. Therefore, here, we aimed to investigate the direct effect of azoramide on insulin signaling in insulin-resistant (IR) cardiomyocytes using IR-modelled ventricular cardiomyocytes. This model was established in H9c2 cells using palmitic acid incubation (50-μM for 24-h). The development of IR in cells was verified by monitoring the cellular 2-DG6P uptake assays in these treated cells. The 2-DG6P uptake was 50% less in the IR-cells compared to the control cells, while azoramide treatment (20-μM for 48-h) could prevent fully that decrease. In addition, azoramide treatment markedly preserved the IR-induced less ATP production and high-ROS production in these IR-cells. Furthermore, this treatment prevented the functional changes in mitochondria characterized by depolarized mitochondrial membrane potential and mitochondrial fusion or fusion-related protein levels as well as cellular ATP level. Moreover, this treatment provided marked protection against IR-associated changes in the insulin signaling pathway in cells, including recovery in the phosphorylation of IRS1 and Akt as well as the protein level of GLUT4 and Akt. Our present results, for the first time, demonstrated that azoramide plays an important protective role in IR-cardiomyocytes, at most, protective action on mitochondria. Therefore, one can suggest that azoramide, as a novel regulator, can provide direct cardioprotection in the IR-heart, at most, via affecting mitochondria and can be a good candidate as a new drug for the treatment of IR-associated cardiovascular disorders in mammalians with systemic IR.

Keywords

Azoramide Insulin signaling Insulin resistance Mitochondria ROS 

Abbreviations

2-DG6P

2-Deoxyglucose6phosphate

Akt

Protein kinase B

ER

Endoplasmic reticulum

GLP-1 receptor

Glucagon-like peptide-1 receptor

GLUT4

Glucose transporter 4

IR

Insulin resistance

IRS1

Insulin-receptor substrate protein 1

ROS

Reactive oxygen species

T2DM

Type 2 diabetes

Notes

Acknowledgements

This study supported by the Scientific Research Project Fund of Cumhuriyet University under the Project number T-668 and Turkish Diabetes Foundation to ENO. BT was supported through the Project of TUBITAK SBAG-216S979.

Compliance with ethical standards

Conflict of interest

No potential conflicts of interest relevant to this article were reported.

References

  1. 1.
    Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909–915CrossRefGoogle Scholar
  2. 2.
    DeFronzo RA (1992) Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35:389–397CrossRefGoogle Scholar
  3. 3.
    Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988–1992.  https://doi.org/10.1056/NEJM199312303292703 CrossRefPubMedGoogle Scholar
  4. 4.
    Boudina S (2013) Cardiac aging and insulin resistance: could insulin/insulin-like growth factor (IGF) signaling be used as a therapeutic target? Curr Pharm Des 19:5684–5694CrossRefGoogle Scholar
  5. 5.
    Rask-Madsen C, Kahn CR (2012) Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol 32:2052–2059.  https://doi.org/10.1161/ATVBAHA.111.241919 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Olgar Y, Degirmenci S, Durak A, Billur D, Can B, Kayki-Mutlu G, Arioglu-Inan E, Turan B (2018) Aging related functional and structural changes in the heart and aorta: MitoTEMPO improves aged-cardiovascular performance. Exp Gerontol 110:172–181.  https://doi.org/10.1016/j.exger.2018.06.012 CrossRefPubMedGoogle Scholar
  7. 7.
    Bhashyam S, Parikh P, Bolukoglu H, Shannon AH, Porter JH, Shen YT, Shannon RP (2007) Aging is associated with myocardial insulin resistance and mitochondrial dysfunction. Am J Physiol Heart Circ Physiol 293:H3063–H3071.  https://doi.org/10.1152/ajpheart.00163.2007 CrossRefPubMedGoogle Scholar
  8. 8.
    Schrauwen P, Hoeks J, Schaart G, Kornips E, Binas B, Van De Vusse GJ, Van Bilsen M, Luiken JJ, Coort SL, Glatz JF, Saris WH, Hesselink MK (2003) Uncoupling protein 3 as a mitochondrial fatty acid anion exporter. FASEB J 17:2272–2274.  https://doi.org/10.1096/fj.03-0515fje CrossRefPubMedGoogle Scholar
  9. 9.
    Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA (1998) TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19:217–231CrossRefGoogle Scholar
  10. 10.
    Group U (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRefGoogle Scholar
  11. 11.
    Heng XP, Yang LQ, Chen ML, Li L, Huang SP, Lei Y (2015) Paradox of using intensive lowering of blood glucose in diabetics and strategies to overcome it and decrease cardiovascular risks. Chin J Integr Med 21:791–800.  https://doi.org/10.1007/s11655-015-0780-5 CrossRefPubMedGoogle Scholar
  12. 12.
    Fu S, Yalcin A, Lee GY, Li P, Fan J, Arruda AP, Pers BM, Yilmaz M, Eguchi K, Hotamisligil GS (2015) Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity. Sci Transl Med 7:292ra98.  https://doi.org/10.1126/scitranslmed.aaa9134 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ruan B, Zhu Z, Yan Z, Yang W, Zhai D, Wang L, Ye Z, Lu H, Xiang A, Liang J, Jiang Y, Xu C, Wang Z, Wei M, Lei X, Cao X, Lu Z (2018) Azoramide, a novel regulator, favors adipogenesis against osteogenesis through inhibiting the GLP-1 receptor-PKA-beta-catenin pathway. Stem Cell Res Ther 9:57.  https://doi.org/10.1186/s13287-018-0771-y CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Szendroedi J, Phielix E, Roden M (2011) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 8:92–103.  https://doi.org/10.1038/nrendo.2011.138 CrossRefPubMedGoogle Scholar
  15. 15.
    Tuncay E, Bitirim CV, Olgar Y, Durak A, Rutter GA, Turan B (2019) Zn(2 +)-transporters ZIP7 and ZnT7 play important role in progression of cardiac dysfunction via affecting sarco(endo)plasmic reticulum-mitochondria coupling in hyperglycemic cardiomyocytes. Mitochondrion 44:41–52.  https://doi.org/10.1016/j.mito.2017.12.011 CrossRefPubMedGoogle Scholar
  16. 16.
    Nobuhara M, Saotome M, Watanabe T, Urushida T, Katoh H, Satoh H, Funaki M, Hayashi H (2013) Mitochondrial dysfunction caused by saturated fatty acid loading induces myocardial insulin-resistance in differentiated H9c2 myocytes: a novel ex vivo myocardial insulin-resistance model. Exp Cell Res 319:955–966.  https://doi.org/10.1016/j.yexcr.2013.02.004 CrossRefPubMedGoogle Scholar
  17. 17.
    Griendling KK, Touyz RM, Zweier JL, Dikalov S, Chilian W, Chen YR, Harrison DG, Bhatnagar A, American Heart Association Council on Basic Cardiovascular S (2016) Measurement of reactive oxygen species, reactive nitrogen species, and redox-dependent signaling in the cardiovascular system: a scientific statement from the American Heart Association. Circ Res 119:e39–e75.  https://doi.org/10.1161/RES.0000000000000110 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Okatan EN, Tuncay E, Turan B (2013) Cardioprotective effect of selenium via modulation of cardiac ryanodine receptor calcium release channels in diabetic rat cardiomyocytes through thioredoxin system. J Nutr Biochem 24:2110–2118.  https://doi.org/10.1016/j.jnutbio.2013.08.002 CrossRefPubMedGoogle Scholar
  19. 19.
    Riehle C, Abel ED (2016) Insulin signaling and heart failure. Circ Res 118:1151–1169.  https://doi.org/10.1161/CIRCRESAHA.116.306206 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kadowaki T, Ueki K, Yamauchi T, Kubota N (2012) SnapShot: insulin signaling pathways. Cell 148:624.  https://doi.org/10.1016/j.cell.2012.01.034 CrossRefPubMedGoogle Scholar
  21. 21.
    Ginsberg HN (2000) Insulin resistance and cardiovascular disease. J Clin Invest 106:453–458.  https://doi.org/10.1172/JCI10762 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Aroor AR, Mandavia CH, Sowers JR (2012) Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 8:609–617.  https://doi.org/10.1016/j.hfc.2012.06.005 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ (2015) Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 313:1973–1974.  https://doi.org/10.1001/jama.2015.4260 CrossRefPubMedGoogle Scholar
  24. 24.
    Abaci A, Kilickap M, Goksuluk H, Karaaslan D, Barcin C, Kayikcioglu M, Ozer N, Yilmaz MB, Sahin M, Tokgozoglu L (2018) Data on prevalence of metabolic syndrome in Turkey: systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors. Turk Kardiyol Dern Ars 46:591–601.  https://doi.org/10.5543/tkda.2018.00878 CrossRefPubMedGoogle Scholar
  25. 25.
    Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171–176.  https://doi.org/10.1172/JCI10583 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Copps KD, White MF (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55:2565–2582.  https://doi.org/10.1007/s00125-012-2644-8 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, Quon MJ (1997) Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol 11:1881–1890.  https://doi.org/10.1210/mend.11.13.0027 CrossRefPubMedGoogle Scholar
  28. 28.
    Roberts DJ, Tan-Sah VP, Smith JM, Miyamoto S (2013) Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J Biol Chem 288:23798–23806.  https://doi.org/10.1074/jbc.M113.482026 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC Jr, Roth RA (1998) Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 273:11937–11943CrossRefGoogle Scholar
  30. 30.
    Hajduch E, Litherland GJ, Hundal HS (2001) Protein kinase B (PKB/Akt)—a key regulator of glucose transport? FEBS Lett 492:199–203CrossRefGoogle Scholar
  31. 31.
    Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731.  https://doi.org/10.1136/bmj.b4731 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Luo M, Langlais P, Yi Z, Lefort N, De Filippis EA, Hwang H, Christ-Roberts CY, Mandarino LJ (2007) Phosphorylation of human insulin receptor substrate-1 at Serine 629 plays a positive role in insulin signaling. Endocrinology 148:4895–4905.  https://doi.org/10.1210/en.2007-0049 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Paz K, Liu YF, Shorer H, Hemi R, LeRoith D, Quan M, Kanety H, Seger R, Zick Y (1999) Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 274:28816–28822CrossRefGoogle Scholar
  34. 34.
    Bakhtiyari S, Meshkani R, Taghikhani M, Larijani B, Adeli K (2010) Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids 45:237–244.  https://doi.org/10.1007/s11745-010-3394-3 CrossRefPubMedGoogle Scholar
  35. 35.
    Yi Z, Langlais P, De Filippis EA, Luo M, Flynn CR, Schroeder S, Weintraub ST, Mapes R, Mandarino LJ (2007) Global assessment of regulation of phosphorylation of insulin receptor substrate-1 by insulin in vivo in human muscle. Diabetes 56:1508–1516.  https://doi.org/10.2337/db06-1355 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Esma Nur Okatan
    • 1
  • Yusuf Olgar
    • 2
  • Erkan Tuncay
    • 2
  • Belma Turan
    • 2
    Email author
  1. 1.Department of Biophysics, Faculty of MedicineCumhuriyet UniversitySivasTurkey
  2. 2.Department of Biophysics, Faculty of MedicineAnkara UniversityAnkaraTurkey

Personalised recommendations